Showing 3651-3660 of 9076 results for "".
Therapeutics Update: Product News
https://practicaldermatology.com/topics/general-topics/therapeutics-update-product-news/21894/Take 5: New Developments in the Realm of STIs and STDs
https://practicaldermatology.com/columns/take-5/take-5-new-developments-in-the-realm-of-stis-and-stds/21969/New data and recent advancements highlight the importance of education and prevention.Take 5: Recent Developments in Systemic Therapy for Psoriasis
https://practicaldermatology.com/columns/recent-developments/take-5-recent-developments-in-systemic-therapy-for-psoriasis/22002/New data reveal noteworthy financial and clinical trends in the use of systemic agents.10 Procedural Tips for Hidradenitis Suppurativa
https://practicaldermatology.com/topics/rare-disease/10-procedural-tips-for-hidradenitis-suppurativa/56430/This guide was created to assist dermatologists who care for patients with HS considering surgery and emphasizes the importance of patient-centered care, expectation setting, and advanced surgical techniques.A Busy Time in the Field
https://practicaldermatology.com/issues/januaryfebruary-2026/a-busy-time-in-the-field/54452/Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
https://practicaldermatology.com/programs/cme/hitting-the-target-in-atopic-dermatitis-interdisciplinary-team-training-for-leveraging-il-13-inhibitors-to-address-the-burden-of-disease/54437/On-demand webcast on the role of interleukin (IL)-13 in atopic dermatitis pathophysiology and strategies for leveraging IL-13 inhibitors to address disease burden and improve patient outcomes.Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Lead from Ahead (For a Change)
https://practicaldermatology.com/topics/practice-management/lead-from-ahead-for-a-change/23973/Access Is Everything
https://practicaldermatology.com/topics/practice-management/access-is-everything/23942/The Safe Step Act of 2023 seeks to rein in fail-first policies and protect patients.